Acute Respiratory Distress Syndrome

Category

FDA Approves EC-18 for Phase 2 Clinical Trials Targeting ARDS in COVID-19 Patients: Led by Duke Infectious Disease Expert Dr. Cameron Robert Wolfe

South Korean-based Enzychem Lifesciences (KOSDAQ: 183490) just announced that the US Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to evaluate its lead therapeutic candidate EC-18, in a Phase 2 clinical trial in...

UCI Investigates Synthetic Vasoactive Intestinal Polypeptide-based Experimental Drug on High Risk SARS-CoV-2 Patients

University of California Irvine, (UCI) recently announced their participation in a COVID-19-focused clinical trial investigating a drug called Aviptadil in at risk patients. Dr. Richard Lee, Interim chief of UCK Health Division of Pulmonary Diseases and Critical Care...

The FDA Approving Experimental Stem Cell Therapies Targeting Patients with Severe COVID-19 Cases

Novel medical innovations are being pursued by biotech companies and clinical investigators to halt COVID-19 causalities as there is, presently, no approved treatment for the novel coronavirus—especially in severe, escalated conditions where mortality is more...

Austrian Biotech’s Investigational Phase II Drug Receives Compassionate Use Approval for COVID-19 ARDS

About 20% of those hospitalized with COVID-19 suffer from acute respiratory distress syndrome (ARDS), a potentially life-threatening complication of the infection with SARS-CoV-2. Consequently, an Austrian biotech has received compassionate use approval from the...